Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation

Affiliations

• ¹ Department of Haematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
• ² Department of Haematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
• ³ Department of Haematology and Institute for Clinical Research, National Hospital Organization Kumamoto Medical Centre, Kumamoto, Japan.
• ⁴ Department of Haematology, Kumamoto Shinto General Hospital, Kumamoto, Japan.
• ⁵ Department of Haematology, National Hospital Organization Kyushu Cancer Centre Hospital, Fukuoka, Japan.
• ⁶ Department of Haematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.
• ⁷ Department of Haematology, Oita Prefectural Hospital, Oita, Japan.
• ⁸ Department of Haematology, Rheumatology and Infectious Disease, Kumamoto University Hospital, Kumamoto, Japan.
• ⁹ Department of Haematology, Imamura General Hospital, Kagoshima, Japan.
• ¹⁰ Department of Haematology, National Cancer Centre Hospital, Tokyo, Japan.
• ¹¹ Department of Haematology and Cell Therapy, Aichi Cancer Centre Hospital, Nagoya, Aichi, Japan.
• ¹² Department of Haematology, Clinical Immunology and Infectious Disease, Ehime University Graduate School of Medicine, Ehime, Japan.
• ¹³ Division of Medical Oncology, Haematology, and Infectious Diseases, Department of Medicine, Fukuoka University Hospital, Fukuoka, Japan.
• ¹⁴ Department of Haematology, National Hospital Organization Nagasaki Medical Centre, Omura, Nagasaki, Japan.
• ¹⁵ Department of Internal Medicine, Heartlife Hospital, Okinawa, Japan.
• ¹⁶ Department of Haematology, Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan.
• ¹⁷ Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
• ¹⁸ Department of Haematology, Sasebo City General Hospital, Sasebo, Nagasaki, Japan.
• ¹⁹ Innovative Clinical Research Centre, Kanazawa University, Kanazawa, Japan.
• ²⁰ Medical Affairs, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan.
• ²¹ Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagoya, Aichi, Japan.